Latest Conference Articles

Daniel Blockmans, MD, PhD, discussed the results of a phase 3 trial that revealed upadacitinib significantly improved outcomes in patients with giant cell arteritis.

At EULAR, Tonix Pharmaceuticals presented the phase 3 RESILIENT trial which met the primary endpoint of TNX-102 SL reducing daily pain intensity.

Amanda Mixon, PA-C, discusses the need to better bridge the rheumatology and dermatology care teams due to overlapping diseases.

Karen Costenbader, MD, discusses the 2 post hoc analyses that demonstrated treatment with belimumab reduces flares and increases response rates among patients with early active SLE.

These data, presented at RAD 2024, highlight the potential of delgocitinib cream for patients with chronic hand eczema in terms of patient and clinician reported outcomes.

Karen Costenbader, MD, discusses how early intervention with belimumab in patients with lupus significantly reduces disease flares and prevents irreversible organ damage.

These findings, presented at RAD 2024, highlight risk of atopic dermatitis patients for developing various cancers as well as major adverse cardiovascular events.

Patients in the spesolimab cohort demonstrated rapid improvements in DLQI scores compared with placebo, which were maintained through week 48.

An analysis of the REALISTIC trial from EULAR 2024 details the effects of certolizumab pegol in rheumatoid arthritis based on rheumatoid factor levels and prior TNF inhibitor use.

These data highlighted which drug, in combination with topical corticosteroids, produced the best efficacy results for those with atopic dermatitis.

Matthew Zirwas, MD, reviews the clinical discrepancies of certain JAK-targeting therapies and their role in dermatology patient outcomes.

Matthew Zirwas, MD, discusses the prospect of pairing JAK inhibitors like ruxolitinib cream with other disease-targeting options for conditions including vitiligo and alopecia areata.

These data, presented at RAD 2024, highlight the potential benefits of upadacitinib for adults and adolescents observed in the Measure Up 1 and Measure Up 2 studies.

Responses were highly durable throughout 4 years of bimekizumab treatment.

Jennifer L. Hsiao, MD, reviews the rapidly growing inventory of investigational drugs for HS.

Matthew Zirwas, MD, explains why he believes agents like ruxolitinib cream and upadacitinib have become the optimal treatments for atopic dermatitis, hidradenitis suppurativa, and more.

Significantly greater improvements were reported at week 2, which were sustained through week 12, in patients receiving the halobetasol propionate/tazarotene lotion compared with the vehicle cohort.

Sidbury covered the similarities and differences between the new guideline updates by the AAD on atopic dermatitis as well as differences with other organizations’ guidelines.

In new late-breaking data, alopecia patients’ real-world incidence of atopic dermatitis was highlighted by investigators.

Overall, 189 (74.1%) patients treated with brodalumab achieved PASI 75, 133 (52.2%) achieved PASI 90, and 98 (38.4%) achieved PASI 100.

Bourjeily told HCPLive at SLEEP 2024 that sleep issues, such as insomnia and restless legs syndrome, are the most common during the first and third trimester of pregnancy.

These data presented at RAD 2024 highlight the differences among eczema patient preferences in terms of administration modes, risk levels, and more.

The first line treatment for restless legs syndrome—dopamine agonists—may be making a patient’s condition worse in the long-term, Winkelman told HCPLive at SLEEP 2024.

An analysis of survey data from more than 200 patients with atopic dermatitis details treatment satisfaction and provider trust based on racial/ethnic backgrounds of patients.

Lisa Swanson, MD, explains how building resiliency is crucial for coping with burnout.

At SLEEP 2024, Kolla shared tips to help his fellow practitioners for improving patient outcomes when dealing with patients with both sleep issues and psychiatric illnesses.

Jennifer L. Hsiao, MD, discusses what the anticipated JAK inhibitors may provide to patients with HS if FDA-approved in the coming years.

This late-breaking data featured at RAD 2024 highlights several improvements in patient reported outcomes observed among atopic dermatitis patients, including itch relief.

Martin spoke about the barriers standing in the way of CPAP adherence in women with sleep apnea at SLEEP 2024.

This interview at RAD 2024 featured a discussion by Bissonnette of recent data related to 4 topical drugs for patients with atopic dermatitis.